Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Stock-Based Compensation
Intercept Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Stock-Based Compensation
$24m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
11%
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$782m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$788m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$650.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Intercept Pharmaceuticals Inc's Stock-Based Compensation?
Stock-Based Compensation
24m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Stock-Based Compensation amounts to 24m USD.
What is Intercept Pharmaceuticals Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
11%
Over the last year, the Stock-Based Compensation growth was -4%. The average annual Stock-Based Compensation growth rates for Intercept Pharmaceuticals Inc have been -25% over the past three years , -15% over the past five years , and 11% over the past ten years .